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Objectives: Research on pain severity and health outcomes, especially health-
related quality of life (HRQoL), is often done in a specific disease area examining spe-
cific domains within HRQoL. Although important, this research says very little about 
the relationship between general pain severity (across conditions) and domains of 
HRQoL. The purpose of this study was to investigate this relationship using a large 
sample of EU patients diagnosed with pain. MethOds: Data came from the 2013 
EU National Health and Wellness Survey (NHWS; n= 62,000). The NHWS is a cross-
sectional general health survey assessed yearly in the 5 EU (UK, France, Spain, Italy, 
and Germany). Those individuals who reported a diagnosis of one or more pain types 
were the focal subsample of this analysis (n= 14,459). Patients’ HRQoL was assessed 
via the SF-36 and their pain in the past week was measured on an 11 point self-
report scale from 0 “no pain” to 10 “pain as bad as you can imagine”. Results: Initial 
descriptive results showed that there were large mean differences in SF-36 domain 
scores for those with a diagnosis of pain vs. those without. The largest differences 
were observed for the bodily pain (M= 40.91 vs. 51.88, p< .001, d= 1.06), general health 
(M= 42.89 vs. 50.68, p< .001, d= .80), and role emotional (M= 43.93 vs. 51.04, p< .001, 
d= .75) scales. With regard to pain severity in the past week, the strongest correla-
tions were observed for the bodily pain (r= -.63, p< .001) and role physical (r= -.46, 
p< .001) scales. After controlling covariates, these associations still held for both the 
bodily pain (β = -.59, p< .001) and role physical scales (β = -.45, p< .001). The nature of 
the association between severity (e.g., linear, quadratic) was also examined for each 
SF-domain score. cOnclusiOns: Results suggest that the association between 
pain severity and HRQoL is nuanced and that pain affects different domains of 
HRQoL to varying degrees.
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Objectives: Children with GHD can experience physical symptoms and disease-
related impacts on functioning and well-being. However, no GHD-specific measures 
exist to assess these impacts. The purpose of this qualitative study was to collect 
data to support the conceptual validity of a new measure, with a patient-reported 
outcome (PRO) version for older children and an observer-reported outcome 
(ObsRO) version for parents/guardians. MethOds: Focus groups and interviews 
were conducted with 39 children (aged 8–12) with GHD, 31 parents of children with 
GHD (aged 4–12) and eight clinical experts in three countries (Germany, UK, US). 
Interviews were analysed and coded using adapted grounded theory to determine 
overarching themes and concepts. Based on the analysis, a conceptual model of 
the impact of GHD was developed and items for both versions generated and then 
cognitively debriefed. Results: Qualitative analysis found the saturation of con-
cepts was reached with four domains of impact: Symptoms, Physical, Social, and 
Emotional. Sub-concepts included appetite (48%), strength (42%) and energy level 
(38%) for Symptoms; limitations in physical performance (58%) and reaching (44%) 
for Physical; mistaken for younger (58%) and teasing (41%) for Social; and worry 
(55%) and self-confidence (41%) for Emotional. Emotional impacts were often related 
to others’ perception or treatment of the child as younger. Children and parents 
reported consistent symptoms/impacts, although severity of impacts sometimes 
varied. Impacts were moderated by factors including velocity of physical growth 
and age at treatment initiation. All versions were cognitively debriefed in a new 
sample (N= 26: 13 children, 13 parents) and, based on findings, it was determined 
that the PRO version was appropriate for children aged 9–12. A 32-item TRIM-CGHD 
(PRO and ObsRO versions) was finalized. cOnclusiOns: The conceptual validity 
of both versions of the TRIM-CGHD is supported by these qualitative findings and 
the measure is now ready for psychometric validation.
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Objectives: To explore impact of weight loss on patient-reported outcomes in indi-
viduals without type 2 diabetes, but with obesity (BMI ≥ 30 kg/m2) or overweight (BMI 
27.0-29.9 kg/m2) with ≥ one comorbidity. Patients were randomised 2:1 to once-daily 
liraglutide 3.0 mg (n= 2487) or placebo (n= 1244) as adjunct to D&E. MethOds: Impact 
of Weight on Quality of Life–Lite (IWQOL-Lite) and Short-Form 36 v2 (SF-36) question-
naires were administered in countries with validated translations (approx. 82% of 
individuals). Data are reported as estimated change at end-of-trial, derived using 
ANCOVA with LOCF; increased scores signify improvement. This post hoc analysis was 
based on categorical weight change from baseline. Results are reported for liraglutide 
3.0 mg, placebo respectively, as follows: A = weight gain; B = weight loss 0−4.9%; C = 
weight loss 5−9.9%; D = weight loss 10−14.9%; E = weight loss ≥ 15%. Results: For 
individuals in the trial overall, greater proportions treated with liraglutide 3.0 mg 
versus placebo were in the higher weight loss categories: A 7.4%, 34.3%; B 29.5%, 38.6%; 
C 30.1%, 16.6%; D 18.7%, 7.0%; and E 14.4%, 3.5%. For those completing the IWQOL-Lite 
(n= 1890 liraglutide 3.0 mg, n= 886 placebo) and SF-36 (n= 1689, n= 796 respectively), 
similar profiles were observed, with liraglutide 3.0 mg achieving higher categorical 
weight loss than placebo. Changes in IWQOL-Lite total score were lowest in the weight 
Objectives: To cluster health status among adults with hemophilia by applying the 
hidden Markov model (HMM) to account for longitudinal changes in quality of life 
scores and to derive utility weights for each cluster. MethOds: Data were obtained 
from the Hemophilia Utilization Group Studies (HUGS), a prospective, multi-center 
observational study conducted from 2005 to 2013. Demographic and clinical char-
acteristics, bleeding frequency and health-related quality of life (SF-12) at initial 
interview and 3-month follow-up visits for 2 years were collected. This analysis 
included data for 211 adults with hemophilia A or B with at least two observations. 
The HMM was adapted to generate the clusters and to fit the observation sequences, 
which consisted of SF-12 physical component scores (PCS) and mental component 
scores (MCS). Utility weights were derived using Brazier’s algorithm by mapping 
SF-12 scores to a SF-6D scale. Results: Mean age was 34.6 ±13.2 years and 59% had 
severe hemophilia. Data in four unique clusters provided the best fit with the model. 
Mean PCS were [54.2±2.5, 57.1±2.4], [50.4±6.5, 47.3±9.6], [32.4±7.7, 54.4±7.1] and MCS 
were [35.3±7.1, 36.8±8.6] from cluster 1 to cluster 4, respectively. Utility weights 
for each cluster were 0.91±0.05, 0.75±0.11, 0.65±0.11 and 0.55±0.08, respectively. At 
baseline, 49 (23%) adults were classified in cluster 1, 63 (30%) in cluster 2, 67 (32%) in 
cluster 3 and 32 (15%) in cluster 4. Being in a worse health cluster was significantly 
associated with unemployment, low household income, having severe hemophilia 
and higher BMI. The mean bleeding frequencies during a 3-month period were 
1.54±2.62, 3.01±4.91, 3.80±4.09 and 4.83±5.69 among those who were assigned to 
cluster 1 to 4, respectively (p< 0.0001). cOnclusiOns: Health status in hemophilia 
can be described by four mutually exclusive and clinically relevant clusters, which 
provide patients’ value of health outcomes for future economic analyses.
PSY87
oPioidS Switch in chronic PAin: imPAct ASSeSSment uSing electronic 
heAlth recordS
Ussai S1, Petelin R2
1Young Against Pain (YAP) Group, Parma, Italy, 2Laboratorio Salute, Naples, Italy
Objectives: Patients with chronic pain frequently require strong opioids for pain 
relief. While most patients achieve adequate analgesia, a significant minority either 
suffers intolerable side effects and/or inadequate pain relief leading to opioid 
switching. The lack of a National Pain Care Registry does not permit a successful 
investigation in this topic. MethOds: Study population included all outpatients 
with chronic pain voluntarily participating in a cloud based medical surveillance 
system. Each patient was anonymously linked through an alphanumeric code to all 
opioid prescription (Anatomical Therapeutic Chemical code N02A) in a 18-month 
period. Chronic use was defined as taking the medication for more than 90 con-
secutive days. The prevalence of chronic use was calculated as the ratio between 
the number of subjects taking the medications more than 90 days consecutively 
and the total number of subjects with at least one opioid prescription. This study 
aims to assess (a) the pattern of opioid chronic use, (b) switching of active sub-
stance. Results: Out of about 2,400 occasional users of opioids analgesics, 41 (1.7%) 
were chronic users. Women represented 70.7% of chronic users (N= 29). A total of 
37 (90.2%) chronic users switched active substance at least once during the study 
period. cOnclusiOns: In this outpatient population, the majority of chronic users 
switched active substance at least once during the study period. These results may 
suggest that poor pain control or/and unintended side effects could be a leading 
cause of active substance switching. Otherwise, for patients with inadequate pain 
relief and intolerable opioid-related toxicity/adverse effects, a switch to an alterna-
tive opioid may be the only option for symptomatic relief. However, the evidence for 
the effectiveness of opioid switching does not appear to be established.
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Objectives: Hemophilia is a hereditary bleeding disorder characterized by 
spontaneous and traumatic bleeding requiring regular or episodic infusion of 
clotting factor. Taking care of a child with hemophilia (CWH) is burdensome for 
caregivers. For the assessment of caregivers’ burden standardized question-
naires are needed. We developed the “Hemophilia associated Caregiver Burden 
Scale” (HEMOCABTM). MethOds: Questionnaire development included: 1) item 
generation (two semi-structured focus groups with 11 caregivers, evaluation of 
existing caregiver burden scales for relevance by 16 HCPs); 2) feasibility test-
ing (cognitive interviews with 12 caregivers) and 3) pilot-testing in caregivers 
of CWH with and without inhibitors < 22 years old (psychometric analysis of 
HEMOCABTM). Results: Item generation resulted in a revised questionnaire 
containing 108 questions pertaining to 13 domains. Forty caregivers (75% moth-
ers) completed the HEMOCABTM (mean age of 39.32±8.9). The majority of CWH 
had hemophilia A (95%), inhibitors (15%), were severely affected by hemophilia 
(77.5%), and had 4.83±8.9 bleeds in the last year. Caregivers reported spending 
8.69±7.7 hours per month on infusion and 3.84±6.7 hours per month travelling to 
the hemophilia centre. Psychometric testing of the HEMOCABTM showed good 
values for reliability (Cronbach’s alpha of TOTAL score: α = .97; ‘FREQUENCY’: α = .95 
and ‘BURDEN’: α = .92) and validity (convergent, known groups). HEMOCABTM 
correlated highly with the IOF (r= -.867 for total score) and revealed signifi-
cant differences among caregivers of CWH with inhibitors vs. without in all 
domains of HEMOCABTM except for ‘school’. Caregivers reported highest bur-
den in the domains ‘perception of child’, ‘emotional stress’ and ‘financial bur-
den’. cOnclusiOns: Based on item and scale analysis 49 items were deleted and 
the final HEMOCABTM consists of 59 items. HEMOCABTM is the first hemophilia-
specific instrument for the assessment of caregiver burden with good psychomet-
ric characteristics in terms of reliability and validity. In a next step we will examine 
the sensitivity to change of the revised HEMOCABTM.
